Investor Relations

Latest News

May 5, 2021

DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2021 Financial Results

View Press Release

Apr 28, 2021

DiaMedica Therapeutics to Report First Quarter 2021 Financials and Provide a Business Update May 6, 2021

Apr 22, 2021

DiaMedica Therapeutics to Participate in the B. Riley Securities’ Neuroscience Conference

View All News

DiaMedica Corporate Presentation

View Presentation

Jun 2, 2021 8:00 am EDT

18th Annual Craig-Hallum Institutional Investor Conference

Add to Calendar View All

Aug 9 – Aug 10, 2021

BTIG Virtual Biotechnology Conference 2021

View All

Nov 2 – Nov 7, 2021

ASN Kidney Week 2021

View All

Company Overview

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) is a clinical stage biopharmaceutical company developing recombinant proteins to improve the lives of patients who experience a stroke or recurrent strokes and kidney diseases.

View Board of Directors

Investor Contact Information

Company

DiaMedica Therapeutics, Inc.
Two Carlson Parkway,
Suite 260
Minneapolis, MN 55447